cas 1393813-42-7, SulfaMide, N-[5-(4-broMophenyl)-6-chloro-4-pyriMidinyl]-N'-propyl-

Articles about 1393813-42-7Total 10 be found

Improved and single-pot process for the synthesis of macitentan, an endothelin receptor antagonist, via lithium amide-mediated nucleophilic substitution
Abstract: An improved, simple, efficient, and telescoped synthesis of macitentan, an endothelin receptor antagonist, starting from 5-(4-bromophenyl)-4,6-dichloropyrimidine in an overall yield of around 62% is described. Graphical abstract: [Figure not available: see fulltext.].
Jagtap, Kunal M.,Niphade, Navnath C.,Gaikwad, Chandrashekhar T.,Shinde, Gorakshanath B.,Toche, Raghunath B.,Joshi, Divyesh R.,Mathad, Vijayavitthal T.
p. 653 - 661
(2018)
Read Online

METHOD FOR PREPARING MACITENTAN AND INTERMEDIATE COMPOUND THEREOF
The present invention relates to technical field of chemical synthesis of drugs, and provides a preparation method of Macitentan and intermediate compound thereof. Adding. THF solution containing compound II and 5-bromo-2-chloropyrimidine slowly into THF
-
Paragraph 0087-0090

(2021/10/02)

A Novel Synthesis of Macitentan, an Endothelin Receptor Antagonist
-
Nami, Majid,Sovari, Sara Nasiri,Haghighatnia, Yaghoub,Dabiri, Minoo,Salehi, Peyman
p. 258 - 264
(2017/06/09)

PROCESS FOR PREPARATION OF MACITENTAN
The present invention relates to a process for the preparation of N-[5-(4-Bromophenyl)- 6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'propylsulfamide or Macitentan of Formula (I). The present invention further relates to a process for the preparation highly pure N-[5- (4-Bromophenyl)-6- [2- [(5 -bromo-2-pyrimidinyl)oxy]ethoxy] -4-pyrimidinyl] - N'propylsulfamide or Macitentan of Formula (I). Said substantially pure Macitentan is useful in the preparation of pharmaceutical composition for the treatment of cardiac disorders.
-
Page/Page column 12; 13

(2017/12/18)

AN IMPROVED PROCESS FOR THE PREPARATION OF MACITENTAN
The present invention relates to an improved process for the preparation of macitentan and pharmaceutical acceptable salts thereof. Further present invention also relates to methylene chloride solvate of macitentan and their use in the preparation of pure macitentan.
-
Page/Page column 21

(2017/09/07)

PROCESS FOR PREPARING AN ENDOTHELIN RECEPTOR ANTAGONIST
The present invention relates to a process for preparing macitentan of Formula (I): to macitentan prepared according to such a process and to macitentan in substantially pure form.
-
Page/Page column 16

(2017/03/14)

PROCESS FOR THE PREPARATION OF MACITENTAN AND INTERMEDIATES THEREOF
The present invention relates to an improved process for preparation of Macitentan and intermediates thereof. The present invention also relates to a novel ammonium salt of Macitentan. The present invention further relates to a process for the preparation of amorphous Macitentan.
-
Page/Page column 22; 23

(2017/01/02)

PROCESS FOR PREPARING A PYRIMIDINE INTERMEDIATE
The present invention relates to a process for preparing a pyrimidine intermediate, namely the compound of formula I-2 or a salt thereof. Said compound of formula I-2 or its salt can be used to prepare macitentan. Macitentan (chemical names: N-[5-(4-bromophenyl)-6-[2-[(5-bromo- 2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl] -N'-propylsulfamide or N-[5-(4-bromophenyl)- 6- {2- [(5 -bromopyrimidin-2-yl)oxy] ethoxy } pyrimidin-4-yl] -N'-propylsulfuric diamide) is an endothelin receptor antagonist that has notably been approved by the US Food and Drug Administration and the European Commission for the treatment of pulmonary arterial hypertension. It has been first disclosed in WO 02/053557. The last step of one of the potential preparation routes described in WO 02/053557, called Possibility A and Possibility B , can be summarised as shown in Scheme Al hereafter.
-
Page/Page column 26

(2015/02/02)

PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN
The present invention relates to a new synthetic intermediate, namely the compound of formula I-2 I or a salt thereof. Said compound of formula I-2 or its salt can be used to prepare the compound of formula I-3 I which is an important synthetic intermediate used in the preparation of macitentan.
-
Page/Page column 24

(2014/10/15)

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist
Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.
Bolli, Martin H.,Boss, Christoph,Binkert, Christoph,Buchmann, Stephan,Bur, Daniel,Hess, Patrick,Iglarz, Marc,Meyer, Solange,Rein, Josiane,Rey, Markus,Treiber, Alexander,Clozel, Martine,Fischli, Walter,Weller, Thomas
p. 7849 - 7861
(2012/10/29)